FDA expands indication for Merck's Emend nausea and vomiting drug
The US Food and Drug Administration (FDA) has approved the use of Merck's single-dose Emend (fosaprepitant dimeglumine) in combination with other antiemetic agents to prevent delayed nausea and vomiting in patients who receive moderately emetogenic chemotherapy (MEC). Emend, a substance P/neurokinin-1 receptor (NK1) antagonist, has already been approved for highly emetogenic chemotherapy.
Click on this link for more information.
